Treatment of Burkitt's lymphoma in HIV-positive patients.
Many Burkitt's-type non-Hodgkin lymphomas (NHL) in patients without HIV infection are curable with current brief high-dose combination chemotherapy regimens. Burkitt's-type lymphomas (BL) comprise 30-40% of HIV-associated NHL. Their morphologic, clinical, cytogenetic and molecular genetic characteristics are similar to those of sporadic BL unassociated with HIV infection. They often occur in less immunosuppressed HIV-infected individuals than the other types of NHL. Most patients with HIV-associated NHL benefit as much from low-dose as from standard or high-dose chemotherapy with less toxicity. However, there may be a subpopulation of HIV-infected patients with Burkitt's-type NHL and well preserved immune status who may benefit from high-dose chemotherapy programs that are effective for BL patients without HIV infection.
Straus
D J
DJ
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000150:complications* / Q000188:drug therapy*; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000150:complications*; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy